Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Trial Profile

Phase 1b/2a Study of OPT-302 in Combination With Aflibercept for Persistent Central-involved Diabetic Macular Edema

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 Jan 2018

At a glance

  • Drugs Aflibercept (Primary) ; OPT 302 (Primary)
  • Indications Diabetic macular oedema
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Opthea
  • Most Recent Events

    • 05 Jan 2018 New source identified and integrated (ClinicalTrials.gov; NCT03397264).
    • 05 Jan 2018 New trial record
    • 03 Jan 2018 According to the Opthea media release, primary analysis of data from this study is anticipated in first half of 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top